Literature DB >> 8177050

Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus.

C Bofill1, J Joven, J Bages, E Vilella, T Sans, P Cavallé, R Miralles, J Llobet, J Camps.   

Abstract

Regardless of type, uncontrolled diabetes represents a serious disruption of fuel homeostasis with consequences throughout the body. This may hamper the applicability of predeposited autologous blood transfusion in diabetic patients because metabolic changes are expected as a consequence of repeated bleeding. We undertook this study to determine whether the presence of non-insulin-dependent diabetes mellitus (NIDDM) influences the erythropoietin (EPO) response to repeated phlebotomies with respect to normal subjects. We included 22 consecutive patients scheduled for major surgery during a 2-year period in which clinical and metabolic complications were excluded and renal and liver function was considered unaffected. Selected biochemical and hematologic variables were serially measured during donation of several units of blood in a 12- to 29-day period. Bleeding produced a significant decrease in serum glucose, cholesterol, triglyceride, and apoprotein B concentration in diabetic patients. Except for glucose, this effect was not observed in controls. Both groups were comparable with respect to initial hemoglobin concentrations and all hematologic variables measured. The decrease in hemoglobin concentration did not produce clinical symptoms in these patients, and recovery was regarded as normal in both groups. Serum EPO levels in diabetic patients were negatively influenced by the initial hemoglobin A1c (HbA1c) proportion. Moreover, three nonrespondent diabetic patients with poor glycemic control responded normally 6 to 13 months later, in a second operation, when glycemic control had improved significantly. In conclusion, NIDDM may limit the donation of requested units for major surgery only if poor glycemic control is present. When possible, phlebotomies should be delayed and metabolic control reinforced.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177050     DOI: 10.1016/0026-0495(94)90204-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  16 in total

Review 1.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

2.  Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse.

Authors:  Robert C Cooksey; Deborah Jones; Scott Gabrielsen; Jingyu Huang; Judith A Simcox; Bai Luo; Yudi Soesanto; Hugh Rienhoff; E Dale Abel; Donald A McClain
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-30       Impact factor: 4.310

Review 3.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

4.  Iron overload inhibits late stage autophagic flux leading to insulin resistance.

Authors:  James Won Suk Jahng; Reham Musaibeh Alsaadi; Rengasamy Palanivel; Erfei Song; Victoria Emily Barbosa Hipolito; Hye Kyoung Sung; Roberto Jorge Botelho; Ryan Charles Russell; Gary Sweeney
Journal:  EMBO Rep       Date:  2019-08-23       Impact factor: 8.807

5.  Sex difference in mouse metabolic response to erythropoietin.

Authors:  Yuanyuan Zhang; Heather M Rogers; Xiaojie Zhang; Constance Tom Noguchi
Journal:  FASEB J       Date:  2017-03-10       Impact factor: 5.191

6.  Adipocyte iron regulates adiponectin and insulin sensitivity.

Authors:  J Scott Gabrielsen; Yan Gao; Judith A Simcox; Jingyu Huang; David Thorup; Deborah Jones; Robert C Cooksey; David Gabrielsen; Ted D Adams; Steven C Hunt; Paul N Hopkins; William T Cefalu; Donald A McClain
Journal:  J Clin Invest       Date:  2012-09-10       Impact factor: 14.808

Review 7.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

8.  The association of biomarkers of iron status with mortality in US adults.

Authors:  A Menke; P Muntner; J M Fernández-Real; E Guallar
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-02-16       Impact factor: 4.222

9.  Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia.

Authors:  Jonghan Kim; Xuming Jia; Peter D Buckett; Sihao Liu; Chih-Hao Lee; Marianne Wessling-Resnick
Journal:  FASEB J       Date:  2012-12-14       Impact factor: 5.191

10.  At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death.

Authors:  Yuichi Masuda; Hirohito Ichii; Nosratola D Vaziri
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.